Vivos Therapeutics (VVOS) and Its Competitors Financial Contrast

Vivos Therapeutics (NASDAQ:VVOS) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare Vivos Therapeutics to related companies based on the strength of its valuation, institutional ownership, risk, dividends, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Vivos Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	-$21.17 million	-0.06
Vivos Therapeutics Competitors	$1.88 billion	$138.21 million	11.30

Vivos Therapeutics’ peers have higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Vivos Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Vivos Therapeutics Competitors	-278.16%	-150.10%	-21.89%

Institutional and Insider Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Vivos Therapeutics has a beta of 6.37, suggesting that its share price is 537% more volatile than the S&P 500. Comparatively, Vivos Therapeutics’ peers have a beta of 2.57, suggesting that their average share price is 157% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vivos Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Vivos Therapeutics Competitors	4264	10506	18254	825	2.46

Vivos Therapeutics currently has a consensus target price of $2.80, suggesting a potential upside of 2,417.99%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 17.36%. Given Vivos Therapeutics’ higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than its peers.

Summary

Vivos Therapeutics peers beat Vivos Therapeutics on 10 of the 13 factors compared.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.